Identifying a combination benefit of a Ph-3 drug with an SOC drug In collaboration with big pharma
Indication prioritization for a CCR6 inhibitor In collaboration with big pharma
Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial
Merck KGaA taps CytoReason’s machine learning platform to profile immuno-oncology drug
Alignment of single-cell trajectories by tuMap enables high-resolution quantitative comparison of cancer samples
Cytoreason and Summit Pharmaceuticals International forge commercial alliance to bring CytoReason’s machine learning model of the immune system for drug discovery & development to Japanese drug makers
Israel’s CytoReason introduces AI clinical drug development platform to Japan’s pharma market
CytoReason Collaborates with Sanofi, Using its AI Technology to Gain Better Understanding of Disease Mechanisms
An Immune System “GPS” Uncovers Pathways to Treat Diseases
CytoReason Announces Collaboration with Ferring to Identify Novel Therapeutic Targets in Inflammatory Bowel Disease Using AI Technology
